Terms: = Head and neck cancer AND FOXP3, AIID, DIETER, IPEX, JM2, PIDX, XPID AND Treatment
88 results:
1. Phenotypic immune characterization of gastric and esophageal adenocarcinomas reveals profound immune suppression in esophageal tumor locations.
Groen-van Schooten TS; Harrasser M; Seidel J; Bos EN; Fleitas T; van Mourik M; Pouw RE; Goedegebuure RSA; Doeve BH; Sanders J; Bos J; van Berge Henegouwen MI; Thijssen VLJL; van Grieken NCT; van Laarhoven HWM; de Gruijl TD; Derks S
Front Immunol; 2024; 15():1372272. PubMed ID: 38638445
[TBL] [Abstract] [Full Text] [Related]
2. Immune checkpoint CD161/LLT1-associated immunological landscape and diagnostic value in oral squamous cell carcinoma.
Hu X; Dong Y; Xie S; Song Y; Yu C; He Y; Wang Z; Hu Q; Ni Y; Ding L
J Pathol Clin Res; 2024 Mar; 10(2):e353. PubMed ID: 38502058
[TBL] [Abstract] [Full Text] [Related]
3. Improved antitumor effects elicited by an oncolytic HSV-1 expressing a novel B7H3nb/CD3 BsAb.
Zhang Z; Yang N; Lu H; Chen Y; Xu L; Wang Z; Lu Q; Zhong K; Zhu Z; Wang G; Li H; Zheng M; Zhang W; Yang H; Peng X; Zhou L; Tong A
Cancer Lett; 2024 Apr; 588():216760. PubMed ID: 38428724
[TBL] [Abstract] [Full Text] [Related]
4. Momordicine-I Suppresses head and neck cancer Growth by Reprogrammimg Immunosuppressive Effect of the Tumor-Infiltrating Macrophages and B Lymphocytes.
Sur S; Bhartiya P; Steele R; Brennan M; DiPaolo RJ; Ray RB
Mol Cancer Ther; 2024 May; 23(5):672-682. PubMed ID: 38315993
[TBL] [Abstract] [Full Text] [Related]
5. B-cell infiltration is associated with survival outcomes following programmed cell death protein 1 inhibition in head and neck squamous cell carcinoma.
Gavrielatou N; Fortis E; Spathis A; Anastasiou M; Economopoulou P; Foukas GRP; Lelegiannis IM; Rusakiewicz S; Vathiotis I; Aung TN; Tissot S; Kastrinou A; Kotsantis I; Vagia EM; Panayiotides I; Rimm DL; Coukos G; Homicsko K; Foukas P; Psyrri A
Ann Oncol; 2024 Apr; 35(4):340-350. PubMed ID: 38159908
[TBL] [Abstract] [Full Text] [Related]
6. Deciphering the immune landscape of head and neck squamous cell carcinoma: A single-cell transcriptomic analysis of regulatory T cell responses to PD-1 blockade therapy.
Miraki Feriz A; Bahraini F; Khosrojerdi A; Azarkar S; Sajjadi SM; HosseiniGol E; Honardoost MA; Saghafi S; Silvestris N; Leone P; Safarpour H; Racanelli V
PLoS One; 2023; 18(12):e0295863. PubMed ID: 38096229
[TBL] [Abstract] [Full Text] [Related]
7. Immunohistological evaluation of patients treated with intra-arterial chemoradiotherapy and surgery for oral cancer.
Ikeuchi Y; Someya M; Hasegawa T; Saito M; Mafune S; Tsuchiya T; Kitagawa M; Gocho T; Dehari H; Ogi K; Sasaki T; Hirohashi Y; Torigoe T; Hirokawa N; Miyazaki A; Sakata KI
Med Mol Morphol; 2023 Dec; 56(4):288-296. PubMed ID: 37507576
[TBL] [Abstract] [Full Text] [Related]
8. Comparison of Clinical Outcomes, Pathologic Characteristics, and Immune-Related Features of Postradiation vs Sporadic Oral Cavity Squamous Cell Carcinoma.
Chow JCH; Cheuk W; Cho WCS; Wong CF; Au DWY; Tam AHP; Wong RCW; Chan JCH; Law SCC; Ngan RKC; Wong KH; Cheung KM
JAMA Netw Open; 2023 Jul; 6(7):e2323890. PubMed ID: 37459093
[TBL] [Abstract] [Full Text] [Related]
9. Prognostic impact of intra- and peritumoral immune cell subpopulations in head and neck squamous cell carcinomas - comprehensive analysis of the TCGA-HNSC cohort and immunohistochemical validation on 101 patients.
Knebel M; Körner S; Kühn JP; Wemmert S; Brust L; Smola S; Wagner M; Bohle RM; Morris LGT; Pandey A; Schick B; Linxweiler M
Front Immunol; 2023; 14():1172768. PubMed ID: 37383237
[TBL] [Abstract] [Full Text] [Related]
10. EGFR Inhibition by Cetuximab Modulates Hypoxia and IFN Response Genes in head and neck Squamous Cell Carcinoma.
Chaudhary R; Slebos RJC; Noel LC; Song F; Poole MI; Hoening DS; Hernandez-Prera JC; Conejo-Garcia JR; Guevara-Patino JA; Wang X; Xie M; Tan AC; Chung CH
Cancer Res Commun; 2023 May; 3(5):896-907. PubMed ID: 37377902
[TBL] [Abstract] [Full Text] [Related]
11. Personal immune profiles: Diversity and prognostic value for oral tongue squamous cell carcinoma evaluated by comprehensive immune parameter analyses with multiplex immunofluorescence.
Daroonpan P; Ouchi R; Zhang C; Nagai S; Nishii N; Kashima Y; Tsushima F; Harada H; Hamagaki M; Ikeda T; Aida J; Kaomongkolgit R; Azuma M
Oral Oncol; 2023 Aug; 143():106458. PubMed ID: 37329869
[TBL] [Abstract] [Full Text] [Related]
12. Tumor microenvironmental modification by the current target therapy for head and neck squamous cell carcinoma.
Okuyama K; Naruse T; Yanamoto S
J Exp Clin Cancer Res; 2023 May; 42(1):114. PubMed ID: 37143088
[TBL] [Abstract] [Full Text] [Related]
13. Spontaneous Murine Model of Anaplastic Thyroid cancer.
Yan H; Ma Y; Zhou X; He Y; Liu Y; Caulin C; Wang L; Xu H; Luo H
J Vis Exp; 2023 Feb; (192):. PubMed ID: 36804915
[TBL] [Abstract] [Full Text] [Related]
14. Primary head and neck cancer cell cultures are susceptible to proliferation of Epstein-Barr virus infected lymphocytes.
Shao S; Scholtz LU; Gendreizig S; Martínez-Ruiz L; Florido J; Escames G; Schürmann M; Hain C; Hose L; Mentz A; Schmidt P; Wang M; Goon P; Wehmeier M; Brasch F; Kalinowski J; Oppel F; Sudhoff H
BMC Cancer; 2023 Jan; 23(1):47. PubMed ID: 36639629
[TBL] [Abstract] [Full Text] [Related]
15. Impact of the combination of sintilimab and chemotherapy on the tumor and paratumor PD-L1, IDO, TIM-3, foxp3+ and CD8 expressions in patients with advanced esophageal squamous cell carcinoma.
Zhang S; Cai H; Huang J; Wang G
Thorac Cancer; 2022 Dec; 13(23):3284-3294. PubMed ID: 36288460
[TBL] [Abstract] [Full Text] [Related]
16. CD8+ and foxp3+ T-Cell Cellular Density and Spatial Distribution After Programmed Death-Ligand 1 Check Point Inhibition.
Curry J; Alnemri A; Philips R; Fiorella M; Sussman S; Stapp R; Solomides C; Harshyne L; South A; Luginbuhl A; Tuluc M; Martinez-Outschoorn U; Argiris A; Linnenbach A; Johnson J
Laryngoscope; 2023 Aug; 133(8):1875-1884. PubMed ID: 36125263
[TBL] [Abstract] [Full Text] [Related]
17. The immune microenvironment of HPV-positive and HPV-negative oropharyngeal squamous cell carcinoma: a multiparametric quantitative and spatial analysis unveils a rationale to target treatment-naïve tumors with immune checkpoint inhibitors.
Tosi A; Parisatto B; Menegaldo A; Spinato G; Guido M; Del Mistro A; Bussani R; Zanconati F; Tofanelli M; Tirelli G; Boscolo-Rizzo P; Rosato A
J Exp Clin Cancer Res; 2022 Sep; 41(1):279. PubMed ID: 36123711
[TBL] [Abstract] [Full Text] [Related]
18. Immune Infiltration-Related ceRNA Network Revealing Potential Biomarkers for Prognosis of head and neck Squamous Cell Carcinoma.
Zhao S; Peng M; Wang Z; Cao J; Zhang X; Yu R; Huang T; Lian W
Dis Markers; 2022; 2022():1014347. PubMed ID: 36097539
[TBL] [Abstract] [Full Text] [Related]
19. Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter study.
Simonelli M; Garralda E; Eskens F; Gil-Martin M; Yen CJ; Obermannova R; Chao Y; Lonardi S; Melichar B; Moreno V; Yu ML; Bongiovanni A; Calvo E; Rottey S; Machiels JP; Gonzalez-Martin A; Paz-Ares L; Chang CL; Mason W; Lin CC; Reardon DA; Vieito M; Santoro A; Meng R; Abbadessa G; Menas F; Lee H; Liu Q; Combeau C; Ternes N; Ziti-Ljajic S; Massard C
ESMO Open; 2022 Oct; 7(5):100562. PubMed ID: 35987165
[TBL] [Abstract] [Full Text] [Related]
20. Neoadjuvant Pembrolizumab and Chemotherapy in Resectable Esophageal cancer: An Open-Label, Single-Arm Study (PEN-ICE).
Duan H; Shao C; Pan M; Liu H; Dong X; Zhang Y; Tong L; Feng Y; Wang Y; Wang L; Newman NB; Sarkaria IS; Reynolds JV; De Cobelli F; Ma Z; Jiang T; Yan X
Front Immunol; 2022; 13():849984. PubMed ID: 35720388
[TBL] [Abstract] [Full Text] [Related]
[Next]
